This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

Traditional fertility benefit practices — like dollar cap benefits and step therapy — are creating inequities in treatment, said Ann Gaines, senior vice president of business development at Progyny. Gaines made these comments Wednesday during the Midwest Business Group on Health conference in Chicago.

Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.

A look at how tapping real world evidence from medical devices and patients could be a game changer, improving patient-clinician communication, supporting earlier interventions and helping patients manage their condition.

Innovative approaches to real world evidence collection present opportunities for medical device companies to improve patient outcomes. But success will depend on improving the way medtech companies integrate digital health. Executives from Abbott, Smith & Nephew, AliveCor and Huma weigh in on these issues.

It is the first LVAD trial to examine five-year outcomes and surpasses a previous Abbott study on HeartMate 3, which recorded a survival time of two years. The device was found to reduce morbidity and mortality, largely because of fewer deaths by stroke, clotting and bleeding.

The nonprofit Digital Medicine Society is partnering with the likes of Google and the FDA to develop a free resource designed to help digital health startups navigate the regulatory process.

Abbott wants to leap into the world of consumer wearables to track various health signals for better health for consumers and better growth of its business. Will it win hearts and minds?

A recent webinar hosted by MedCity News and sponsored by BioT shared insights on some of the ingredients to successful creation and execution of remote patient monitoring solutions supported by a cloud-based connected care platform with speakers from BioT and Abbott.

A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks. 

With the results of a recent trial, Abbott is seeking an expanded indication from the FDA for its CardioMEMS device, intended to prevent hospitalizations in patients with heart failure.  It’s also hoping to win over national coverage from CMS. 

Abbott received FDA clearance for an app to pair with its Freestyle Libre 2 glucose monitor. The app lets people get readings directly on their phone without using a reader.

Abbott announced the launch of the newly-approved NeuroSphere Virtual Clinic by which deep brain stimulation patients can have their devices programmed and reset remotely, from the comfort of their homes without having to travel to a specialist.

False negatives increase the risk that patients will not self-isolate or exercise other precautions — such as wearing a mask — and make more people sick than if they had had an accurate diagnosis.

NPR reported on the study by The Cleveland Clinic’s Dr. Gary Procop, which has not been peer reviewed. Procop acknowledged that he had stored samples in a special solution not recommended by the company, which defended the ID NOW test.

In a public health crisis such as the Covid-19 pandemic, each healthcare vertical is playing […]

The diagnostics company said it had received the EUA for use of its ID NOW system, which can detect a positive result in as low as five minutes and a negative result in 13 minutes. ID NOW is mainly used in urgent care settings.

American pharma companies — architects of the opioid crisis in the United States and avid hunters of new markets — stand at the ready to feed and fuel demand for painkillers in India where attitudes toward pain toleration have changed.

Dexcom’s executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.

A sooner-than-expected availability of a rival’s continuous glucose monitoring system to Medicare patients sends Dexcom’s stocks lower, but an analyst believes this will be temporary.

Although DexCom actually was the first to get FDA approval for a continuous glucose monitor with its G5 model last year, it requires finger sticks to calibrate the device.  

In a new report, the Health Care Council of Chicago, an initiative of Matter and Leavitt Partners, outlined the current status of Chicago’s healthcare ecosystem.

Assessing mild traumatic brain injury with a blood test could be tremendously useful for the military. More than 360,000 service members have suffered a TBI since 2000, and diagnosing them has often been inexact

Abbott has swallowed up St. Jude Medical for $25 billion and while analysts find the deal to be a positive one, historically large M&As rarely pan out.

Abbott Vascular’s Absorb bioresorbable stent that disappears into the body over time seems to be coming up short compared with the company’s durable drug-eluting stent, Xience.

Abbott’s Absorb is a long-awaited, much-hyped technology to battle coronary artery disease, but its immediate success is not guaranteed.

FDA approves Absorb, first fully bioresorbable polymer stent, which will heat up competition with Boston Scientific’s partially absorbable version.